Published in Cancer Weekly, August 26th, 2003
The grant has a total potential value of approximately $0.6 million over 2 years. The activities funded by this grant complement current studies and phase I/II clinical trials the company is conducting by providing analog epitopes that extend vaccine coverage to larger segments of the population. The grant was made under the NCI's Flexible System to Advance Innovative Research for Cancer Drug Discovery by Small...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.